TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03110718

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ArmeoP+real MV
Description: All the subjects assigned to the experimental received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air (Vibraplus; @Circle, San Pietro in Casale, Italy) (fig. 2) wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude (approximately 2mm in indentation depth, mean pressure of 250mBar, which effectively induce inhibition of the monosynaptic reflex) so that it was just below the threshold for perceiving an illusory movement. We chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ArmeoP+real MV
Description: All the subjects assigned to the experimental received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air (Vibraplus; @Circle, San Pietro in Casale, Italy) (fig. 2) wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude (approximately 2mm in indentation depth, mean pressure of 250mBar, which effectively induce inhibition of the monosynaptic reflex) so that it was just below the threshold for perceiving an illusory movement. We chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
Study: NCT01984047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3050002
Description: GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3050002
Description: GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3050002
Description: GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3050002
Description: GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3050002
Description: GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3050002
Description: GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion
Study: NCT02271893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextromethorphan
Description: The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
Study: NCT00664482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-006
Description: Autologous Therapy for Pancreatic Cancer
Study: NCT00841061

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: electrolytic iron
Description: 1/4 a cup of cereal fortified with electrolytic iron per day between the ages of 112 days and 280 days of age

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: ferrous fumarate
Description: 1/4 cup of cereal fortified with ferrous fumarate to be fed per day between ages of 112 days and 280 days of age
Study: NCT03847831

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active School Flag Program
Description: Schools enrolled in the program take part in the 17 actions described in the PPASF.
Study: NCT04451005

Intervention type: OTHER
Intervention: 0
Description: Elderly patients with sarcopenia
Study: NCT04038294

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ISOlution protein supplement
Description: EXPERIMENTAL ARM: Protein supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Supplement
Description: PLACEBO COMPARATOR ARM: Placebo supplement to be re-constituted and consumed twice daily for a minimum of 2 weeks pre-procedure, twice daily during post-operative recovery and 2 times daily for 8 weeks after the patient is discharged home
Study: NCT04301323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHVI1 eye drops
Description: Including 35 children enrolled to receive BHVI1 eye-drops once nightly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHVI2 eye drops
Description: Including 35 children enrolled to receive BHVI2 eye-drops once nightly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHVI3 eye drops
Description: Including 35 children enrolled to receive BHVI3, combination of BHVI1 and BHVI2, eye-drops once nightly
Study: NCT01749527

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: minimal activity
Description: Pad test with minimal activity
Study: NCT02524561

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEE pill
Description: Conjugated equine estrogens 0.45 mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estradiol patch
Description: Climara 50 mcg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Progesterone
Description: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Progesterone
Description: Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo patch
Description: placebo patch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo patch
Description: placebo patch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo progesterone
Description: placebo progesterone
Study: NCT00811720

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: as-needed use, tablets, orally, 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalmefene
Description: 18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
Study: NCT02581436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: kSORT assay based follow-up
Description: kSORT assay in pre-established days: 14, 45, 90, 180, 365 and 540 of post transplantation follow-up. If kSORT result is positive maintenance immunosuppressive will be increased (tacrolimus trough levels 12-15 ng/mL, Mofetil Mycophenolate 1.5 mg every 24 hours and prednisone 5 mg/day) and graft biopsy will be obtained. Kidney biopsy will be obtained one mo after treatment as well as kSORT assay. If kSORT result is negative, the maintenance immunosuppressor dosages will remain as established in our institutional guidelines. If after a year of follow-up, the kSORT result is negative, immunosuppression will be decreased (Tacrolimus levels 5 - 10 ng/ml and mofetil mycophenolate 500 mg every 12 hours).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard follow-up
Description: Surveillance will be the usual, includes creatinine determinations and clinical evaluation as often as established in the institutional protocol. A kidney graft biopsy will be obtained in case of dysfunction (increase in serum creatinine \>25% above baseline or 0.3 mg/mL above baseline) or as part of our institutional programmed biopsies (months 3 and 12). Treatment will be established in accordance with biopsy results. In all cases of rejection a kidney biopsy will be obtained one month after initiating treatment. In this control group, samples for kSORT analysis will be collected on pre-established dates for the study, but patient treatment will not be contingent on the assay's results; investigators will be blinded to the result in this control patient group.
Study: NCT01107067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustanon
Description: 250 mg/21 days
Study: NCT03487016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Arm A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Arm A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Arm B Arm C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Arm B Arm C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposomal Injection
Description: Arm B Arm C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Liposomal Injection
Description: Arm B Arm C

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Arm C
Study: NCT02597530

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TEAS
Description: According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TEAS
Description: According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.

Intervention type: DEVICE
Group type: OTHER
Intervention: TEAS
Description: According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
Study: NCT03589287

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chondrochymal®
Description: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chondrochymal®
Description: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chondrochymal®
Description: Allogeneic Bone Marrow Derived Mesenchymal Stem Cells
Study: NCT02701309

Intervention type: DEVICE
Intervention: Non-invasive Iron detection device via Zinc-Protoporphyrin
Description: In this study the feasability, sensitivity and specifity of a non-invasive detection method of zinc-protoporphyrin in children is evaluated. It´s a one-arm study, without control Group. Children are aged between 9m and 5y and have a clinical blood sampling indicated.
Study: NCT00737932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Laquinimod
Description: Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Matching placebo for 8 weeks of treatment
Study: NCT03962959

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TBS
Description: TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TBS
Description: TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: TBS
Description: TMS is a non-invasive brain stimulation technique. The primary aim of the study will be to verify the deliverability of the TMS effect on the hippocampus and determine which stimulation protocol is more beneficial to each participant.
Study: NCT02365181

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: intra-articular local anesthetic infiltration
Description: intra-articular local anesthetic infiltration with 20 ml of Ropivacaine 2 % and catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: inter-scalene block
Description: inter-scalene block with 20 ml of Ropivacaine 2 % and catheter

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 %
Description: 20 ml of Ropivacaine 2 %

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 2 %
Description: 20 ml of Ropivacaine 2 %
Study: NCT05101811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D Levels measurement using chemiluminescent assay
Description: Measurement of serum vitamin D levels

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D Levels measurement using chemiluminescent assay
Description: Measurement of serum vitamin D levels

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitamin D level assessment
Description: Using lIAISON DEVICE

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitamin D level assessment
Description: Using lIAISON DEVICE
Study: NCT01757301

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assisted Symptom Management (ASM)
Description: There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Symptom Management (CSM)
Description: This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only).
Study: NCT03954912

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MAKO assisted unicondylar knee arthroplasty
Description: MAKO assisted

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NAVIO assisted unicondylar knee arthroplasty
Description: NAVIO assisted
Study: NCT02356536

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Agilitas
Description: WCD trial
Study: NCT02389465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram + Celecoxib
Description: Participants will receive celecoxib in addition to escitalopram

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram + Placebo
Description: Participants will receive a placebo in addition to escitalopram.
Study: NCT03596788

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate Beverage
Description: The carbohydrate beverage will supply approximately 100 grams of carbohydrate per day (in the form of glucose and fructose)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Beverage
Description: The placebo beverage will contain aspartame.
Study: NCT02002988

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endomyocardial BT injection
Study: NCT03318445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: All participants will take rucaparib by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: All participants will take rucaparib by mouth

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Patients in the dose escalation phase, and patients in the dose expansion phase who have received prior PARP inhibitor therapy, will be given irinotecan by in combination with rucaparib.
Study: NCT01559545

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: Immediate release metronidazole 500 mg orally three times a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole-DRF1
Description: Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole-DRF2
Description: Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
Study: NCT03089047

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Transfusion of rejuvenated and washed autolgous RBCs
Description: Rejuvenation refers to the process of adding a mix of solutes (Rejuvesol®, Citra Labs, Braintree, MA; consists of sodium pyruvate, inosine, adenine, mono- and dibasic sodium phosphate) to older, stored (i.e., 2-3 DPG-depleted) blood to immediately restore 2,3-DPG and ATP levels in the stored red blood cells15. Rejuvenation was originally developed to prolong the storage life of rare-phenotype RBC units. It is FDA-approved for use in RBC units stored in CPD, CPDA-1, and AS-1. The major contraindication for the use of Rejuvesol® is in RBC units stored for fewer than 6 days due to high baseline 2,3-DPG and ATP levels. Rejuvenated units must be washed prior to administration to remove residual Rejuvesol that is not approved for iv administration in such concentrations.
Study: NCT03089047

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Transfusion of washed autolgous RBCs
Description: Autologous RBCs will be washed prior to transfusion to maintain blinding and equalize volume and Hct with the rejuvenated and washed intervention arm
Study: NCT00700908

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: automated telephone intervention vs. usual care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: automated telephone intervention vs. usual care
Study: NCT02091635

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Motilitone)
Description: Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Motilitone
Description: Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
Study: NCT02985177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INF2.0 + IBU
Description: Analgesics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: INF1.0 + IBU
Description: Analgesics
Study: NCT03853967

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose CT scan
Description: low dose CT scan
Study: NCT03806530

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gabapentin
Description: 100 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: 100 mg capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropinirole
Description: 0.50 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropinirole
Description: 0.50 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gabapentin
Description: Placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gabapentin
Description: Placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ropinirole
Description: Placebo capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ropinirole
Description: Placebo capsule
Study: NCT06085235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: cycling exercise for 15min, with 5min warm up
Study: NCT03888378

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.3% Topical Minocycline Ointment
Description: 0.3% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Topical Minocycline Ointment
Description: 1% Topical Minocycline ointment to treat inflamed Meibomian Gland Dysfunction

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Topical Vehicle Ointment
Description: Topical vehicle ointment to treat inflamed Meibomian Gland Dysfunction